Nuon Therapeutics Inc., a San Mateo, Calif.-based developer of drugs for treatment of autoimmune and chronic inflammatory diseases and pain, has raised $27 million in Series B funding. Frazier Healthcare Ventures and Domain Associates co-led the round, and was joined by return backers GBS Venture Partners (
Nuon Therapeutics Inc., a clinical stage biotechnology company focused on novel therapies for autoimmune and chronic inflammatory diseases and pain, today announced the completion of a $27 million Series B financing led by Frazier Healthcare Ventures and Domain Associates LLC. The previous Series A investor, GBS Venture Partners of Australia, also participated. Nuon Therapeutics was represented in the transaction by Wilson, Sonsini, Goodrich & Rosati.
The Series B funding will enable Nuon Therapeutics to advance its orally active lead compound, tranilast, through Phase II clinical trials and support the discovery and development of additional compounds. In 2007, Nuon Therapeutics raised $5 million in its Series A round.
“We are pleased to have such a well-regarded syndicate of investors backing our development activities,” said Rodney Pearlman, Ph.D., CEO of Nuon Therapeutics. “These firms have extensive experience with biotechnology companies at our stage and we look forward to utilizing their expertise and support as we move tranilast into new clinical applications.”
Tranilast is currently marketed for the treatment of asthma and atopic dermatitis in
“We are very excited about the possibilities presented by tranilast in autoimmune indications, and made this investment based upon the long clinical history of tranilast and its efficacy profile in models of autoimmune disease,” said Alan Frazier, founder and Managing Partner of Frazier Healthcare Ventures.
About Nuon Therapeutics
Nuon Therapeutics, Inc. is a clinical stage biotechnology company that develops innovative small molecule drugs that address critical, unmet needs in autoimmune disease and pain. Nuon Therapeutics’ initial programs, based on an exclusive license to technology developed by Imperial College London and
For additional information, please visit: www.nuontherapeutics.com.
About Frazier Healthcare Ventures
Founded in 1991 and with more than $1.8 billion of capital under management, Frazier Healthcare is one of the nation’s leading providers of venture and growth equity capital to emerging healthcare companies. Having invested in more than 100 emerging healthcare companies, Frazier Healthcare is well known for its depth of experience and the technical expertise of its investment team. This experience encompasses product development and launch, clinical trial implementation and design, industry operating experience, academic research and clinical practice. Partnering with Frazier Healthcare provides access to capital and an unparalleled breadth of relevant healthcare industry experience. For more information, please visit www.frazierhealthcare.com.
About Domain Associates, L.L.C.
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus in healthcare. With $2.1 billion of capital under management, Domain has offices in
About GBS Venture Partners
Nuon Therapeutics, Inc. Rodney Pearlman, Chief Executive Officer 650-208-3478 email@example.com